Huettmann, Andreas and Rekowski, Jan and Mueller, Stefan P. and Hertenstein, Bernd and Franzius, Christiane and Mesters, Rolf and Weckesser, Matthias and Kroschinsky, Frank and Kotzerke, Joerg and Ganser, Arnold and Bengel, Frank M. and La Rosee, Paul and Freesmeyer, Martin and Hoeffkes, Heinz-Gert and Hertel, Andreas and Behringer, Dirk and Prange-Krex, Gabriele and Griesshammer, Martin and Holzinger, Jens and Wilop, Stefan and Krohn, Thomas and Raghavachar, Aruna and Maschmeyer, Georg and Brink, Ingo and Schroers, Roland and Gaska, Tobias and Bernhard, Helga and Giagounidis, Aristoteles and Schuette, Jochen and Dienst, Ariane and Hautzel, Hubertus and Naumann, Ralph and Klein, Alfred and Hahn, Dennis and Poepperl, Gabriele and Grube, Matthias and Marienhagen, Joerg and Schwarzer, Andreas and Kurch, Lars and Hoehler, Thomas and Steiniger, Heike and Nueckel, Holger and Suedhoff, Thomas and Roemer, Wolfgang and Brinkmann, Marcus and Ose, Claudia and Alashkar, Ferras and Schmitz, Christine and Duerig, Jan and Hoelzer, Dieter and Joeckel, Karl-Heinz and Klapper, Wolfram and Duehrsen, Ulrich (2019) Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. ANNALS OF HEMATOLOGY, 98 (4). pp. 897-907. ISSN 0939-5555, 1432-0584
Full text not available from this repository. (Request a copy)Abstract
Standard first-line treatment of aggressive B cell lymphoma comprises six or eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus eight doses of rituximab (R). Whether adding two doses of rituximab to six cycles of R-CHOP is of therapeutic benefit has not been systematically investigated. The Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial investigated the ability of [F-18]-fluorodesoxyglucose PET scanning to guide treatment in aggressive non-Hodgkin lymphomas. Patients with B cell lymphomas and a negative interim scan received six cycles of R-CHOP with or without two extra doses of rituximab. For reasons related to trial design, only about a third underwent randomization between the two options. Combining randomized and non-randomized patients enabled subgroup analyses for diffuse large B cell lymphoma (DLBCL; n=544), primary mediastinal B cell lymphoma (PMBCL; n=37), and follicular lymphoma (FL) grade 3 (n=35). With a median follow-up of 52months, increasing the number of rituximab administrations failed to improve outcome. A non-significant trend for improved event-free survival was seen in DLBCL high-risk patients, as defined by the International Prognostic Index, while inferior survival was observed in female patients below the age of 60years. Long-term outcome in PMBCL was excellent. Differences between FL grade 3a and FL grade 3b were not apparent. The results were confirmed in a Cox proportional hazard regression model and a propensity score matching analysis. In conclusion, adding two doses of rituximab to six cycles of R-CHOP did not improve outcome in patients with aggressive B cell lymphomas and a fast metabolic treatment response.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FOLLICULAR LYMPHOMA; ELDERLY-PATIENTS; MAINTENANCE; MULTICENTER; CYCLOPHOSPHAMIDE; TRANSPLANTATION; CHEMOTHERAPY; PREDNISOLONE; VINCRISTINE; DOXORUBICIN; Diffuse large B cell lymphoma; Primary mediastinal B cell lymphoma; Follicular lymphoma; Rituximab; R-CHOP; Survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Abteilung für Nuklearmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Apr 2020 06:52 |
| Last Modified: | 15 Apr 2020 06:52 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27306 |
Actions (login required)
 |
View Item |
